Last reviewed · How we verify

Otsuka Pharmaceutical Development & Commercialization, Inc. — Portfolio Competitive Intelligence Brief

Otsuka Pharmaceutical Development & Commercialization, Inc. pipeline: 8 marketed, 0 filed, 27 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 27 Phase 3 8 Phase 2 13 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Aripiprazole or other oral antipsychotics Aripiprazole or other oral antipsychotics marketed Atypical antipsychotic Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (agonist) Psychiatry
Abilify MyCite® Abilify MyCite® marketed Atypical antipsychotic with digital adherence monitoring Dopamine D2 receptor, serotonin 5-HT1A receptor Psychiatry
OBR OBR marketed Atypical antipsychotic (depot formulation) Dopamine D2 receptor (partial agonist) Psychiatry / Neurology
Lithium or Valproate with Aripiprazole Lithium or Valproate with Aripiprazole marketed Atypical antipsychotic combined with mood stabilizers Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); inositol monophosphatase, GSK-3 (lithium); histone deacetylase (valproate) Psychiatry
Paroxetine CR Paroxetine CR marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Neurology
Lamotrigine + Aripiprazole Lamotrigine + Aripiprazole marketed Anticonvulsant/mood stabilizer + atypical antipsychotic combination Voltage-gated sodium channels (lamotrigine); dopamine D2/D3 receptors (aripiprazole) Psychiatry/Neurology
Quetiapine or Risperidone + Aripiprazole Quetiapine or Risperidone + Aripiprazole marketed Atypical antipsychotic Dopamine D2 receptor, serotonin 5-HT2A receptor Psychiatry
Stimulant Therapy Stimulant Therapy marketed
Aripiprazole IM Depot Aripiprazole IM Depot phase 3
JNT-517 Tablet JNT-517 Tablet phase 3 5-HT2C receptor agonist 5-HT2C receptor Obesity / Metabolic Disease
Brexpiprazole (OPC-34712) Brexpiprazole (OPC-34712) phase 3 Atypical antipsychotic; serotonin-dopamine activity modulator (SDAM) Dopamine D2 receptor (partial agonist); serotonin 5-HT1A receptor (partial agonist); serotonin 5-HT2A receptor (antagonist) Psychiatry/Neurology
Aripiprazole (BMS-337039) Aripiprazole (BMS-337039) phase 3 Atypical antipsychotic Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist) Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 3 shared drug classes
  2. Otsuka Pharmaceutical Co., Ltd. · 2 shared drug classes
  3. AbbVie · 2 shared drug classes
  4. Eli Lilly and Company · 2 shared drug classes
  5. Massachusetts General Hospital · 2 shared drug classes
  6. Medical University of Vienna · 2 shared drug classes
  7. AstraZeneca · 2 shared drug classes
  8. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Otsuka Pharmaceutical Development & Commercialization, Inc.:

Cite this brief

Drug Landscape (2026). Otsuka Pharmaceutical Development & Commercialization, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/otsuka-pharmaceutical-development-commercialization-inc. Accessed 2026-06-10.

Related